All cancer-associated antigens are considered when curating epitopes for CEDAR, including mutated antigens (e.g. neoantigens), oncoviral antigens (e.g. HPV), cancer germline antigens (e.g. MAGE, PRAME, NY-ESO-1), differentiation or tissue-specific antigens (e.g. MART-1, gp100, CEA, prostate antigens), and overexpressed antigens (e.g. Her2/neu, Survivin, wildtype p53) (15). This evidence concerns the gene PRAME and cancer.